A Phase 4 interventional study of VitaFlow+GDMT and J-Valve+GDMT in AORTIC VALVE DISEASES, Aortic Regurgitation and Transcatheter Aortic Valve Replacement (TAVR), sponsored by Ruijin Hospital. Recruiting at 4 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Ruijin Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.
Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 6 that started in 2025, is the only one in phase 4, reaches primary completion later than 6 of the 16 other live ones, and was the 11th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 116 across the 11 interventional studies, 3,750 across the 12 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 2 studies filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453849Chinese Academy of Medical Sciences, Fuwai HospitalTAVR for Aortic Regurgitation Under TEE Guidance | 2026-12-31 |
| NCT06818084Ruijin HospitalTRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Aortic Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, multicenter, non-randomized controlled trial, planning to enroll 180 patients with pure native aortic regurgitation. On the basis of standardized medical therapy, patients will be assigned in a 1:1 ratio to undergo transfemoral transcatheter aortic valve replacement (TF-TAVR) . This prospective, multicenter trial aims to evaluate the safety and effectiveness of transfemoral TAVR using the VitaFlow™ self-expanding valve system compared to dedicated transcatheter devices in patients with PNAR.
The primary endpoint is a composite of all-cause mortality, disabling stroke, and rehospitalization for heart failure, myocardial Infarction, and requiring dialysis or valve reoperation at 12 months post-procedure.
Secondary endpoints include procedure-related complications, long-term clinical events, patient functional status and quality of life, bioprosthetic valve imaging follow-up, echocardiographic parameters, and treatment costs. All endpoint definitions conform to the Valve Academic Research Consortium-3 (VARC-3) criteria
The purpose of this study is to evaluate the safety and efficacy of TF-TAVR for the treatment of isolated aortic regurgitation. The study will compare all-cause mortality, cardiovascular mortality, stroke, rehospitalization for heart failure, and renal failure requiring dialysis treatment at 12 months after TAVR. Additionally, the study will assess the incidence of hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) via CTA, as well as the aortic valve root-prosthesis coaxiality. Changes and differences between groups in the following parameters will be evaluated using transthoracic echocardiography at 6 and 12 months after enrollment: left ventricular ejection fraction (Simpson method), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), estimated aortic valve orifice area, valvular regurgitation, and transvalvular pressure gradient compared with baseline. The study will also compare changes and differences between groups in the Minnesota Living with Heart Failure Questionnaire, Social Support Rating Scale (SSRS), International Physical Activity Questionnaire (IPAQ), and 6-minute walk test (6MWT) at 6 and 12 months after enrollment compared with baseline. Furthermore, the study will compare surgical costs, potential complication costs, and disease-related costs between the two groups.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
This study's planned enrollment of 120 is close to the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Browse Aortic Valve Insufficiency studies →Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Compared within Aortic Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria Age ≥ 60 years. Symptomatic moderate-to-severe or greater isolated aortic regurgitation.
Asymptomatic moderate-to-severe or greater isolated aortic regurgitation meeting at least one of the following criteria:
≤ 55% (measured by biplane Simpson's method); LVESD > 50 mm ; LVESDi > 22 mm/mm²; LVESVi > 45mL/m2 Anatomical suitability for TAVR as assessed by the heart team. Provision of written by the patient or their legal guardian, with agreement to the treatment plan and willingness and ability to comply with all required follow-up assessments.
Exclusion Criteria Incomplete coronary revascularization. Less than 30 days of guideline-directed medical therapy at maximally tolerated doses.
\< 1 year. LVEF \< 45%. \< 30 mL/min/1.73m². Known allergy or to required medications (e.g., aspirin, clopidogrel, warfarin) or contrast media.
Any condition that precludes contrast-enhanced CT. Concurrent moderate-to-severe or severe valvular heart disease other than aortic regurgitation.
Poor patient compliance, unable to complete follow-up as required. Any other condition that, in the investigator's judgment, would make the patient unsuitable for the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet the inclusion and exclusion criteria will undergo TAVR using the VitaFlow™ self-expanding valve system.
Combination Product: VitaFlow+GDMT
Patients who meet the inclusion and exclusion criteria will undergo TF-TAVR using dedicated transcatheter device J-Valve system.
Combination Product: J-Valve+GDMT
The patient will undergo transcatheter aortic valve replacement on the basis of guideline-directed medical therapy with The VitaFlow™ system. The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
The patient will undergo transfemoral aortic valve replacement on the basis of guideline-directed medical therapy with The J-Valve system (Jie ChengMedical Technologies, Suzhou, China). The J-Valve system is a second-generation self-expand able device composed of a porcine bioprosthetic aortic valve and a transfemoral delivery sheath. The valve is supported by a self-expanding nitinol structure. The different valve sizes are 21, 23, 25, 27, 29 and 34 mm. Three U-shaped nitinol graspers were designed to surround the valve.
Clinical worsening
The primary endpoint is a composite of all-cause mortality, disabling stroke, and rehospitalization for heart failure, myocardial Infarction, and requiring dialysis or valve reoperation at 12 months post-procedure.
Time frame: 12 months
Rate of procedural complications
The rate of any aortic dissection, annular rupture, coronary artery occlusion, vascular complications, permanent pacemaker implantation, reoperation of heart valve.
Time frame: 12 months
6-minute walk distance
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.
Time frame: 12 months
New York Heart Association (NYHA) functional class
Classification of function capacity of the NYHA.
Time frame: 12 months
Rate of hypoattenuated leaflet thickening
The rate of hypoattenuated leaflet thickening. Hypoattenuated leaflet thickening(HALT)defined by VARC-3
Time frame: 12 months
Rate of reduced leaflet motion
Rate of reduced leaflet motion. Reduced leaflet motion(RLM)defined by VARC-3.
Time frame: 12 months
Rate of Stroke
Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.
Time frame: 12 months
Mortality
All-cause, cardiovascular, and non-cardiovascular mortality
Time frame: 12 months
Rate of bleeding complications
Rate of bleeding complications. The original VARC definitions with BARC classifications
Time frame: 12 months
Rate of prothetic valve dysfunction
The rate of any prothetic aortic valve stenosis, prothesis-patient mismatch, prosthetic aortic valve regurgitation
Time frame: 12 months
Rate of rehospitalization
The rate of rehospitalization due to valve-related symptoms or worsening congestive heart failure.
Time frame: 12 months
Quality of life assessment (Minnesota Living with Heart Failure Questionnaire, MLHFQ)
Total score of Minnesota Living with Heart Failure Questionnaire (MLHFQ). The total score ranges from 0 to 105, with higher scores indicating a greater impact of heart failure on quality of life and worse outcome..
Time frame: 12 months
Quality of life assessment (social supporting raing scal, SSRS)
Total score of social supporting raing scal (SSRS). The total score ranges from 0 to 40, with higher scores indicating a higher level of social support.
Time frame: 12 months
Quality of life assessment (International Physical Activity Questionnaire, IPAQ)
Total score of International Physical Activity Questionnaire (IPAQ). The total score is calculated by multiplying the frequency and duration of each activity by its respective MET value, and then summing these products. The result is a measure of the total energy expenditure from physical activity in MET-minutes per week.The total score can be used to classify individuals into different physical activity levels, such as low, moderate, or high.
Time frame: 12 months
Treatment costs
Including surgical costs, potential complications costs, and disease-related costs
Time frame: 12 months
Left ventricular ejection fraction (Simpson's method)
Transthoracic echocardiography measurement of left ventricular ejection fraction (Simpson's method). Unit: %
Time frame: 12 months
Left ventricular end-diastolic volume index
Transthoracic echocardiography measurement left ventricular end-diastolic volume index (LVEDVi). Unit: milliliters per square meter (mL/m²)
Time frame: 12 months
Left ventricular end-systolic volume index
Transthoracic echocardiography measurements of left ventricular end-systolic volume index (LVESVi). Unit: milliliters per square meter (mL/m²)
Time frame: 12 months
Left ventricular end-diastolic diameter
Transthoracic echocardiography measurements of left ventricular end-diastolic diameter (LVEDd). Unit: millimeters
Time frame: 12 months
Left ventricular end-systolic diameter
Transthoracic echocardiography measurements of left ventricular end-systolic diameter (LVESd). Unit: millimeters
Time frame: 12 months
Aortic valve orifice area
Transthoracic echocardiography measurement of aortic valve orifice area. Unit: square centimeters
Time frame: 12 months
Transvalvular pressure gradient of aortic valve
Transthoracic echocardiography measurement of transvalvular pressure gradient of aortic valve. Unit: mmHg
Time frame: 12 months
Plan to share: Undecided
Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.